Literature DB >> 30689956

The association of inflammatory markers and echocardiographic parameters in Behçet's disease.

Ali Nazmi Çalık1, Kazım Serhan Özcan1, Banu Mesci2, Tufan Çınar3, Yiğit Çanga1, Barış Güngör1, Mukaddes Kavala4, Aytekin Oğuz2, Osman Bolca1, Ömer Kozan1.   

Abstract

Background: The main objective of the current study is to find out if any association exists between specific inflammatory markers such as homocysteine (Hcy) and pentraxin-3 (PTX-3) and cardiac involvement determined by means of echocardiographic parameters in patients with Behçet disease (BD).
Methods: From January 2011 to January 2012, a total of 62 Behçet's patients were enrolled in the study. Thirty-two healthy subjects constituted the control group. The diagnosis of BD was made as proposed by International Study Group of BD.
Results: The mean PTX-3, Hcy, and C-reactive protein levels were significantly higher in patients with BD compared to the control group. The electromechanical delay (EMD) times were found to be prolonged in patients with BD. Also, the aortic stiffness index (SI) and elastic modulus (Ep) were significantly higher, while the aortic dispensibility was significantly lower in patients with BD. The left atrial volume, left atrial volume index, E/A ratio, E/E' septal, IRight-EMD, PA'-ML, PA'-MS, PA'-TL, SI, and Ep were correlated with PTX-3 levels. In addition, the E/A, PA'-ML, PA'-MS, SI, and Ep displayed correlation with Hcy levels in patients having BD.
Conclusion: Elevated levels of PTX-3 and Hcy were found to be correlated with cardiac involvement determined by means of echocardiographic parameters in patients with BD.

Entities:  

Keywords:  Behçet disease; Pentraxin-3; aortic stiffness; atrial conduction times; diastolic functions; homocysteine

Year:  2019        PMID: 30689956     DOI: 10.1080/00015385.2018.1560071

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  1 in total

1.  Pentraxin 3 levels and correlation with disease severity in patients with acute rheumatic fever.

Authors:  Dolunay Gürses; Merve Oğuz; Münevver Yilmaz; Hülya Aybek; Funda Akpinar
Journal:  Arch Rheumatol       Date:  2021-01-14       Impact factor: 1.472

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.